NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Phases |
NCT03332498 |
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers |
Colon Cancer|Colorectal Cancer|Colorectal Carcinoma|Colon Disease |
Drug: Pembrolizumab
Drug: Ibrutinib |
H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC|Merck Sharp & Dohme Corp. |
Phase 1
Phase 2 |
NCT03331198 |
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004) |
Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Small Lymphocytic |
Biological: JCAR017|Biological: JCAR017 + ibrutinib|Drug: Standard of care |
Juno Therapeutics, Inc. |
Phase 1
Phase 2 |
NCT03330795 |
Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant |
Primary Immunodeficiency|PID |
Biological: CD3/CD19 neg allogeneic BMT |
National Institute of Allergy and Infectious Diseases (NIAID)|University of Pittsburgh |
Phase 1
Phase 2 |
NCT03332849 |
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus |
Type1 Diabetes Mellitus|Type2 Diabetes Mellitus |
Biological: HM12470 |
Hanmi Pharmaceutical Company Limited |
Phase 1 |
NCT03332836 |
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus |
Type 2 Diabetes Mellitus |
Biological: HM12460A |
Hanmi Pharmaceutical Company Limited |
Phase 1 |
NCT03332017 |
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma |
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma |
Drug: BGB-3111|Drug: obinutuzumab |
BeiGene |
Phase 2 |
NCT03331341 |
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma |
Classical Hodgkin Lymphoma |
Drug: Dacarbazine|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Vinblastine |
University of Washington|National Cancer Institute (NCI) |
Phase 2 |
NCT03330457 |
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing |
Bleeding |
Biological: Andexanet alfa (bolus)|Drug: Betrixaban 80 mg PO QD|Biological: Andexanet alfa (infusion IV) |
Portola Pharmaceuticals |
Phase 2 |
NCT03330405 |
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors |
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors |
Drug: Avelumab Phase 1b|Drug: Talazoparib Phase 1b|Drug: Avelumab Phase 2|Drug: Talazoparib Phase 2 |
Pfizer |
Phase 2 |
NCT03330327 |
Molar Potency Study of HM12470 in Healthy Subjects |
Healthy Subjects |
Biological: HM12470 |
Hanmi Pharmaceutical Company Limited |
Phase 1 |
NCT03330314 |
Molar Potency Study of HM12460A in Healthy Subjects |
Healthy Volunteers |
Biological: HM12460A |
Hanmi Pharmaceutical Company Limited |
Phase 1 |
NCT03330197 |
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG |
Pediatric Brain Tumor|Diffuse Intrinsic Pontine Glioma |
Biological: Ad-RTS-hIL-12|Drug: oral veledimex |
Ziopharm |
Phase 1 |
NCT03329560 |
Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV |
HIV-1-infection |
Biological: Oral fecal microbiota transplantation |
The University of Texas Health Science Center, Houston |
Phase 1 |
NCT03326856 |
ET-01 in Subjects With Lateral Canthal Lines |
Lateral Canthal Lines|Crow's Feet |
Biological: botulinum toxin, Type A|Biological: Vehicle |
Eirion Therapeutics Inc. |
Phase 2 |
NCT03331562 |
A SU2C Catalyst? Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer |
Pancreatic Cancer|Pancreas Adenocarcinoma|Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma |
Drug: Pembrolizumab|Drug: paricalcitol|Drug: placebo |
Translational Genomics Research Institute|Stand Up To Cancer|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03329378 |
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer |
Locally Advanced Breast Cancer |
Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Pegfilgrastim|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide |
Icahn School of Medicine at Mount Sinai |
Phase 2 |
NCT03332576 |
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer |
Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer |
Biological: DPX-Survivac|Biological: DPX-Survivac(Aqueous)|Drug: Cyclophosphamide |
ImmunoVaccine Technologies, Inc. |
Phase 1 |
NCT03329846 |
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma |
Melanoma|Skin Cancer |
Drug: BMS-986205|Biological: Nivolumab|Drug: Placebo |
Bristol-Myers Squibb |
Phase 3 |
NCT03332667 |
MIBG With Dinutuximab |
Neuroblastoma |
Radiation: 131I-MIBG|Drug: Ch14.18 Monoclonal Antibody |
New Approaches to Neuroblastoma Therapy Consortium|United Therapeutics |
Phase 1 |